Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

CVS Health

Sanofi

These three stocks are solid value picks in different areas of healthcare.

3 Top Healthcare Stocks to Buy for March

Amgen Inc. (NASDAQ:AMGN) is an American multinational biopharmaceutical company.

This Biotech Stock Has Grown its Dividend Since 2011

Amgen Inc. ( AMGN , Financial) is a well-known pharma and biotech player. The company has been delivering a string of decent financial results, and the most recent quarter was no exception, with Amgen reporting its total revenues were up 4% and its sales volume increased by as much as 8%.

Amgen: Don't Rule Out This Pharma Major Yet

Amgen (AMGN) closed the most recent trading day at $228.59, moving +1.5% from the previous trading session.

Amgen (AMGN) Gains But Lags Market: What You Should Know

THOUSAND OAKS, Calif., March 2, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will virtually present at the 42nd Annual Cowen Healthcare Conference at 11:10 a.m.

AMGEN TO PRESENT AT THE 42ND ANNUAL COWEN HEALTHCARE CONFERENCE

THOUSAND OAKS, Calif., March 2, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.94 per share dividend for the second quarter of 2022.

AMGEN ANNOUNCES 2022 SECOND QUARTER DIVIDEND

Boeing

Caterpillar

Salesforce

Chevron

Disney

Goldman Sachs

Intel

JPMorgan Chase & Co

Coca-Cola

Merck

Microsoft

NIKE

Visa

Verizon

Walgreens

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration."

Dogs Of The Dow For March Drop Closer To Buy Points

Blackrock Inc

Home Depot

Illinois Tool Works

Mastercard

Oracle

Texas Instruments

UnitedHealth Group

Union Pacific

This monthly series ranks a selection of dividend growth stocks in Dividend Radar and presents the ten top-ranked stocks for consideration.

10 Dividend Growth Stocks For February 2022

THOUSAND OAKS, Calif., Feb. 26, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase 3 and PATHWAY Phase 2b trials showed TEZSPIRE™ (tezepelumab-ekko) demonstrated reductions in the annualized asthma exacerbation rate (AAER) across biomarker subgroups of patients with severe asthma.1 These findings support the role of TEZSPIRE as a first-in-class treatment for a broad population of people living with severe asthma, irrespective of biomarker levels.1 In the pooled analysis, TEZSPIRE, when added to standard of care (SoC), reduced asthma exacerbations in patients, irrespective of baseline blood eosinophil counts, demonstrating consistent efficacy with a 71% (≥300 cells per microliter), 48% (

NEW DATA FURTHER REINFORCE EFFICACY OF TEZSPIRE™ (TEZEPELUMAB-EKKO) IN A BROAD POPULATION OF SEVERE ASTHMA PATIENTS

THOUSAND OAKS, Calif., Feb. 22, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the issuance of its inaugural $750 million green bond, with a 3.000% semi-annual coupon and maturing in 2029, to advance the environmental goals that are part of Amgen's environmental, social and governance (ESG) framework.

AMGEN ISSUES INAUGURAL GREEN BOND TO ADVANCE ESG GOALS

Doximity

Novocure

Healthcare is the smart play in this bear market. Here's why these three Fool.com contributors like Doximity, Amgen, and Novocure.

Scared of the Bear? Buy These 3 Healthcare Stocks

A business's management is an important, if not the most important, part of an investment decision.

Amgen: Putting Its Management Through Buffett's $1 Test

THOUSAND OAKS, Calif., Feb. 16, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has been named to Newsweek magazine's list of "America's Most Responsible Companies" for the third consecutive year; JUST Capital's list of "America's Most JUST Companies" for the fifth consecutive year; Barron's list of "America's Most Sustainable Companies" for the second consecutive year; and the Human Rights Campaign Foundation's list of "Best Places to Work for LGBTQ+ Equality" for the sixth consecutive year.

AMGEN RECOGNIZED FOR OUTSTANDING ESG PERFORMANCE

Japan's regulatory agency recently authorized Lumakras as a treatment for a type of lung cancer.

Amgen Snags Another Approval for This Promising Cancer Drug

Amgen Inc (NASDAQ: AMGN) announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in KRAS G12C-mutated advanced pancreatic cancer patients who received Lumakras (sotorasib).  The data will be presented at the American Society of Clinical Oncology (ASCO) Plenary Series.

Amgen Posts Latest Batch of Lumakras Data In Pancreatic Cancer

THOUSAND OAKS, Calif., Feb. 14, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS G12C-mutated advanced pancreatic cancer who received LUMAKRAS® (sotorasib)*.

LUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL

Abbott Labs

Baxter

Cerner

Quest Diagnostics

Eli Lilly

Pfizer

Stryker

If any investor has stood the test of time, it is Warren Buffett, and with good reason.

10 Health Care Stocks Warren Buffett Owns That Offer Safety and Dependable Dividends

Atmos Energy

Ford Motor Company

Johnson & Johnson

Walmart

These seven top defensive growth stocks are among the best options for investors looking for growth, but with a risk-off perspective. The post 7 Defensive Growth Stocks to Buy for February appeared first on InvestorPlace.

7 Defensive Growth Stocks to Buy for February

Waste Management

The U.S. inflation jumped to 7.5% in January but that doesn't necessarily have to mean “losses” for equity investors. According to Grace Capital's Catherine Faddis, the following three stocks have significant upside amidst inflationary pressures to keep those profits pouring in.

Pro: buy these stocks to hedge against inflation

AbbVie

Bristol-Myers

Vertex Pharmaceuticals

Here we discuss five big pharma/biotech companies - SNY, ABBV, BMY, AMGN and VRTX - with the potential to drive investors' wealth higher in 2022 on the back of strong fundamentals.

Will the Rally of These 5 Big Drugmakers Continue in 2022?

Dow Inc

Dow Jones components are known to be financially stable blue-chip companies, which means they can make for great long-term holds.If you're interested in exploring these types of equities, here are 3 dependable Dogs of the Dow to buy now

3 Dependable Dogs of the Dow to Buy Now

Amgen has a long track record of producing market-beating shareholder returns. Its newer drugs and biosimilars offer plenty of promise, and management has maintained aggressive share buybacks.

Amgen: A Rich Dividend Dream Stock Getting Attractive

Amgen (AMGN) outlines a strategy to grow its business through the end of this decade on the back of strong demand for existing products and potential of novel pipeline candidates targeting diverse indications.

Amgen (AMGN) Provides Strong Long-Term Outlook, Shares Up

Starbucks

Zoom Video

Airbnb

DexCom

Illumina

JD.com

Lucid Group

Tech stocks got off to a positive start Wednesday morning. The Nasdaq traded up about 1.3%, the S&P 500 was up 1.04% and the Dow traded 0.7% higher shortly after the opening bell.

Wednesday Morning's 14 Tech Stock Movers Include Amgen, Starbucks and Zoom

News for Amgen Stock (AMGN)